← Patent-cliff monitor small molecule BRUKINSA ZANUBRUTINIB
Loss of exclusivity January 2043 latest FDA-listed patent expiry
Company BEONE MEDICINES USA INC
Drug detail Brand name BRUKINSA Active ingredient ZANUBRUTINIB Strength 160MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval June 2025 Marketing status RX
Listed patents Patent Expires Type 11896596 January 2043 use U-3716 11786531 January 2043 use U-3716 11911386 January 2043 use U-3875 12233069 June 2040 product 11701357 June 2039 use U-3860 11970500 August 2037 use U-2145 11851437 August 2037 substance, product 10927117 August 2037 substance, product 11884674 August 2037 use U-2145 11591340 August 2037 use U-3729 11142528 April 2034 product 10570139 April 2034 use U-2145 9447106 April 2034 substance, product
Regulatory exclusivity Code Expires ODE* March 2031 ODE* January 2030 ODE* September 2028 ODE* August 2028 I-936 March 2027 ODE* November 2026 I-817 January 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.